Liquidia (NASDAQ:LQDA) Insider Sanjeev Khindri Sells 1,185 Shares

Liquidia Corporation (NASDAQ:LQDA) insider Sanjeev Khindri sold 1,185 shares of Liquidia stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $71.51, for a total transaction of $84,739.35. Following the sale, the insider directly owned 65,947 shares in the company, valued at $4,715,869.97. The trade was a 1.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sanjeev Khindri also recently made the following trade(s):

• On Monday, June 8th, Sanjeev Khindri sold 4,134 shares of Liquidia stock. The stock was sold at an average price of $65.46, for a total transaction of $270,611.64.

Liquidia Stock Performance

Shares of LQDA opened at $76.49 on Wednesday. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. Liquidia Corporation has a one year low of $14.04 and a one year high of $82.96. The company has a 50-day simple moving average of $66.37 and a two-hundred day simple moving average of $47.52. The firm has a market capitalization of $6.80 billion, a PE ratio of 546.40 and a beta of 0.55.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. The company’s revenue for the quarter was up 4187.1% compared to the same quarter last year. On average, analysts anticipate that Liquidia Corporation will post 3.02 EPS for the current fiscal year.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Recent commentary notes that Liquidia’s Yutrepia has had a strong commercial debut, suggesting early traction in its pulmonary arterial hypertension market opportunity. Can LQDA’s Yutrepia Drive Growth in the Competitive PAH Market?
• Neutral Sentiment: An investor letter from Laughing Water Capital mentioned Liquidia in a broader portfolio update, but did not provide a clear company-specific catalyst. Here’s Laughing Water Capital’s Updates on Liquidia Corp. (LQDA)
• Negative Sentiment: Multiple insiders, including the CEO, CFO, general counsel, and other executives, sold shares on July 13 in pre-arranged 10b5-1 transactions tied to tax withholding from vesting equity awards. While these sales were planned and not necessarily a bearish signal, the size and breadth of the sales may still pressure investor sentiment. SEC filing – Roger Jeffs sale

Hedge Funds Weigh In On Liquidia

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Liquidia by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after purchasing an additional 1,700 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Liquidia by 10.7% in the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock worth $12,703,000 after purchasing an additional 82,955 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Liquidia by 15.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after purchasing an additional 16,022 shares in the last quarter. Creative Planning lifted its holdings in shares of Liquidia by 40.7% during the second quarter. Creative Planning now owns 26,840 shares of the company’s stock valued at $334,000 after purchasing an additional 7,765 shares in the last quarter. Finally, Legal & General Group Plc boosted its position in shares of Liquidia by 13.4% during the second quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock valued at $1,174,000 after buying an additional 11,111 shares during the last quarter. 64.54% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

LQDA has been the topic of a number of research reports. Wells Fargo & Company boosted their target price on shares of Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Jefferies Financial Group reissued a “buy” rating and set a $60.00 price target on shares of Liquidia in a research report on Monday, May 11th. Oppenheimer set a $75.00 price objective on shares of Liquidia in a research note on Friday, June 5th. Needham & Company LLC upped their price objective on shares of Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Finally, HC Wainwright raised their target price on shares of Liquidia from $67.00 to $75.00 and gave the company a “buy” rating in a research note on Friday, June 5th. Three equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $68.88.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).